Skip to main content

Advanced Search

Haematologica
  • Home
  • Current Issue
  • Ahead Of Print
  • Archive
  • Submit a Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Submit a Manuscript
    • Track a Manuscript
  • About Us
    • About Haematologica
    • Editorial Board
    • Our Policies
  • More
    • Advertising
    • Rights & Permissions
    • Alerts
    • Feedback
    • Contact
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
Siham Bibi, Melis Dilara Arslanhan, Florent Langenfeld, Sylvie Jeanningros, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Luba Tchertanov, Richard Moriggl, Peter Valent, Michel Arock
Haematologica March 2014 99: 417-429; doi:10.3324/haematol.2013.098442
Siham Bibi
Molecular Oncology and Pharmacology, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melis Dilara Arslanhan
Molecular Oncology and Pharmacology, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florent Langenfeld
Molecular Oncology and Pharmacology, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France Bioinformatics, Modelisation and Molecular Dynamics, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Jeanningros
Molecular Oncology and Pharmacology, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabine Cerny-Reiterer
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emir Hadzijusufovic
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria Internal Medicine, Small Animal Clinic, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luba Tchertanov
Bioinformatics, Modelisation and Molecular Dynamics, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Moriggl
Ludwig Boltzmann Institute of Cancer Research, Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Valent
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Arock
Molecular Oncology and Pharmacology, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France Laboratory of Hematology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. Siham Bibi1,
  2. Melis Dilara Arslanhan1,
  3. Florent Langenfeld1,2,
  4. Sylvie Jeanningros1,
  5. Sabine Cerny-Reiterer3,4,
  6. Emir Hadzijusufovic3,4,5,
  7. Luba Tchertanov2,
  8. Richard Moriggl6,
  9. Peter Valent3,4 and
  10. Michel Arock1,7⇑
  1. 1Molecular Oncology and Pharmacology, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France
  2. 2Bioinformatics, Modelisation and Molecular Dynamics, LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, France
  3. 3Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Austria
  4. 4Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria
  5. 5Internal Medicine, Small Animal Clinic, Department for Companion Animals and Horses, University of Veterinary Medicine Vienna, Austria
  6. 6Ludwig Boltzmann Institute of Cancer Research, Vienna, Austria
  7. 7Laboratory of Hematology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
  1. Correspondence: arock{at}ens-cachan.fr
View Abstract
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Data supplements

  • Disclosures and Contributions

    Files in this Data Supplement:

    • Adobe PDF - 2013_098442-Disclosures.pdf
    • Adobe PDF - 2013_098442-Contributions.pdf

ARTICLE FIGURES & DATA

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Representation of the structure of KIT, illustrating the known function of its domains and the localization of the more frequently observed mutations in the KIT sequence in pediatric or adult patients with mastocytosis. The receptor is presented under its monomeric form, whereas its wild-type counterpart dimerizes upon ligation with SCF before being activated in normal cells. The KIT D816V PTD mutant is found in up to 90% of the adult patients, whereas the ECD mutants are found in nearly 40% of the affected children. ECD: extracellular domain; Ins: Insertion; ITD: internal tandem duplication; JMD: juxtamembrane domain; KI: kinase insert; TK1: tyrosine kinase domain 1 (ATP binding site); TK2: tyrosine kinase domain 2 (activation loop) = PTD (phosphotransferase domain); TMD: transmembrane domain.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Major signal transduction pathways activated by the mutant KIT D816V receptor. The mutant receptor is represented under its monomeric form and at the cell membrane, although it remains unclear if it is present mainly in the cytoplasm or at the cell membrane in malignant mast cells, and if it is active under monomeric and/or dimeric form. Note the prominent role of STAT5 and AKT signaling in the proliferation induced by constitutive activation of the KIT receptor. It has been recently postulated that STAT5 can be directly activated by the mutant KIT receptor in the absence of JAK proteins (blue curved arrow). Moreover, STAT1 and STAT3 homo- and heterodimers were shown to be activated by mutant KIT and these can interact on higher order chromatin structures with STAT5 complexes so called STAT-Oligomers. STAT5 is efficiently dimerized and translocated to the nucleus upon full phosphorylation, which requires both tyrosine and serine phosphorylation as indicated by small orange circle or asterix. The cytoplasmic retention of pSTAT5 via the GAB2 scaffold protein was demonstrated to control PI3K-AKT signaling and this mechanism is important for survival of neoplastic mast cells, but it also slows down the transcription through nuclear pSTAT5. Furthermore, the lipid phosphatase PTEN (3′-inositol phosphatase and tensin homolog) further regulates negatively AKT signaling by dephosphorylation of PIP3. Other prominent signaling pathways triggering transcription factor changes in the nucleus such as forkhead family member phosphorylation which then leaves the nucleus upon AKT phosphorylation or RAS-RAF-MAPK signaling and their influence on transcription factor activation by phosphorylation events such as Serum response factor (SRF), AP-1 (Jun/Fos/ATF-1 homo- or heterodimers) is also illustrated. Moreover, unphosphorylated STAT5a was recently shown to interact with heterochromatin protein 1 (HP1α) and this mechanism protects DNA from noxias through keeping the densely packed chromatin, but pSTAT5 opens up chromatin most likely by its ability to induce oligomers via the N-terminus (black circles labeled with N and a dimerizer itself) and loop formation on DNA. This culminates into STAT5 target gene induction and most prominent genes known to be under control of STAT5 signaling in MC are exemplified, which leads to survival and growth.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Effects of BCR-ABL1 (p210) functional domains on downstream signaling effectors. BCR-ABL1 signaling leads to enhanced proliferation, reduced apoptotic potential, and altered cell adhesion. Contributions from both BCR and ABL domains on downstream signaling are illustrated. OLI: oligomerization domain; S/T kinase: serine/threonine kinase; DH: Dbl homology; PH: Pleckstrin homology; SH2 or SH3: Src homology 2/3; TK kinase: tyrosine kinase; DBD: DNA binding domain; ABD: actin binding domain. Note the central place occupied by both AKT and STAT5 (red circle) in the signal transduction pathways leading to altered apoptosis and enhanced proliferation of CML cells.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    General structure of the PKB/AKT and STAT5a/b proteins. (A). AKT. All the PKB isoforms possess the kinase domain in the central region of the molecule. The PH (pleckstrin homology) domain acts as a phosphoinositide-binding module. The hydrophobic motif (HM) is located at the carboxyl-terminus adjacent to the kinase domain. Phosphorylation sites in the activation loop of the kinase domain and the hydrophobic motif are indicated. Length of the protein and positions of the phosphorylation sites may vary depending on the isoform. (B). Domain structure of the STAT5a/b isoforms. The N-terminal domain (ND), which prevents autoactivation and is the docking domain to cytokine receptors is known to interact with nuclear hormone receptors such as the glucocorticoid receptor (GR; similarly progesterone (PR), estrogen (ER), androgen (AR) and mineralocorticoid receptor (MR) might follow similar rules of docking to the STAT5 N-terminus, which is postulated due to close homology to the GR, but experimentally largely not precisely mapped). Moreover, the N-terminus of STAT5 is a dimerization domain that can execute higher order chromatin structures by STAT oligomerization and co-factor recruitment, where particular interaction with a histone methylase involved in many cancers called EZH2 is of significance. The coiled-coil dimerization domain (CCD) was reported to be involved in repression together with the extreme C-terminus and here SMRT co-repressor interaction was mapped. Moreover, it is crucial for transrepression in context of a RARalpha fusion oncoprotein found in AML patients and Nmi-mediated histone acetyl transferase activity through p300/CBP interaction was also linked to this domain. Moreover, p300/CBP are also bound by the C-terminus, which is also called transactivation and protein activity domain since tyrosine phosphatases recognize the end domain around the critical pY. The C-terminus binds also other proteins which were mapped and it is a domain that also undergoes acetylation, sumoylation and serine phosphorylation plus splicing or proteolytic processing. The SH2 domain (SD) is important for stable parallel dimer formation and efficient nuclear transport and DNA binding complex formation and the laboratory of Patrick Gunning used this domain for specific STAT inhibitors successfully.11 The DNA binding domain (DBD) is in the middle and separated by a linker domain (LD) from the SH2 domain. Apart from critical tyrosine phosphorylation, also Serine phosphorylation (shown in red) is important for myeloid transformation with regard to STAT5a and STAT5b proteins. Of further importance are findings of gain of function mutations in STAT5b found in patients with large granulocytic leukemia (N642H or Y665F) both present in the SH2 domain. Finally, gain of function mutations like the STAT5a/b S710/S715F oncogenic variants were described elsewhere47 and originate from retroviral screens to make IL-3-dependent myeloid cells factor independent.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Activation of growth factor receptor protein tyrosine kinases results in autophosphorylation on tyrosine residues. PI3K is recruited to the membrane by directly binding to phosphotyrosine consensus residues of growth factor receptors or adaptors through one or both SH2 domains in the adaptor subunit. This leads to allosteric activation of the catalytic subunit. Activation results in production of the second messenger phosphatidylinositol (PtdIns)-3,4,5-trisphosphate (PIP3). The lipid product of PI3K, PIP3, recruits a subset of signaling proteins with pleckstrin homology (PH) domains to the membrane, including PDK1 and AKT. PTEN (a PI 3,4,5-P3 phosphatase) negatively regulates the PI3K/AKT pathway. Once activated, AKT mediates the activation and inhibition of several targets, resulting in cellular survival, growth and proliferation through various mechanisms.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    The canonical and non-canonical JAK-STAT pathway and its subversion by BCR-ABL or mutant KIT. Cytokine receptors, devoid of any tyrosine kinase activity, are constitutively linked to members of the JAK protein family. JAK kinases are cytoplasmic kinases where many cancer driver mutations of constitutively active JAK kinases have been mapped acting in a similar fashion like cytoplasmic fusion kinases such as BCR-ABL1 or the transforming membrane TK mutant KIT D816V. Upon activation of the cytokine receptor by ligand binding, conformational changes occur in the intracytoplasmic tail of the receptor, leading to activation of JAKs by auto- and transphosphorylation. Activated JAKs phosphorylate many substrates, among which are also the essential STAT proteins. Parallel STAT dimers are thought to be efficiently transported into the cell nucleus viaassociating with importins, bind then to specific DNA sequences and to activate the transcription through many cell type specific protein partners on target gene regulatory loci. This canonical pathway can be diverted in the presence of mutant KIT receptors (particularly, but not only KIT D816V), or by BCR-ABL1, both oncogenic proteins being able to phosphorylate STAT5 without JAK involvement (red arrows) by direct tyrosine phosphorylation via their kinase domain. This cascade of signalization is negatively regulated by at least three different families of proteins: protein tyrosine phosphatases (PTPs: SHP, CD45, PTP1B/TC-PTP and overall poorly studied), SOCSs (suppressors of cytokine signaling: CIS, SOCS1–SOCS3) or PIAS proteins (protein inhibitors of activated stats). PTPs dephosphorylate and recycle STAT5, while SOCS and CIS proteins bind either to the STAT5 activating receptors or they bind rather to the TKs. STATs are also negatively regulated by protein inhibitors of activated STAT (PIASs), which act in the nucleus through several mechanisms. For example, PIAS1 and PIAS3 inhibit transcriptional activation by STAT1 and STAT3, respectively, by binding and blocking access to the DNA sequences they recognize. Moreover, two non-canonical pSTAT5 cytoplasmic retention systems were found to be present in CML and/or neoplastic MCs, namely pSTAT5 retention by SRC and HCK kinases or docking to the p85 regulatory subunit of PI3K via the GAB2 scaffold protein that controls then AKT signaling. These cytoplasmic retention systems might block nuclear accumulation of pSTAT5, keeping STAT5-mediated transcription at bay.

Tables

  • Figures
  • Table 1.

    WHO Classification of mastocytosis.

    Table 1.
PreviousNext
Back to top

Vol 99 Issue 3

Haematologica: 99 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word about Haematologica.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
(Your Name) has forwarded a page to you from Haematologica
(Your Name) thought you would like to see this page from the Haematologica web site.
Print
Citation Tools
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
Siham Bibi, Melis Dilara Arslanhan, Florent Langenfeld, Sylvie Jeanningros, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Luba Tchertanov, Richard Moriggl, Peter Valent, Michel Arock
Haematologica Mar 2014, 99 (3) 417-429; DOI: 10.3324/haematol.2013.098442

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Siham Bibi, Melis Dilara Arslanhan, Florent Langenfeld, Sylvie Jeanningros, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Luba Tchertanov, Richard Moriggl, Peter Valent, Michel Arock
Haematologica Mar 2014, 99 (3) 417-429; DOI: 10.3324/haematol.2013.098442
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Alert me when this article is cited
  • Alert me if a correction is posted

Jump To

  • Article
    • Abstract
    • Introduction
    • Mast cells and mastocytosis
    • Chronic myelogenous leukemia
    • The phosphoinositide 3-kinase (PI3K)-AKT pathway
    • JAK-STAT signaling
    • Conclusions and future perspectives
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

More in this TOC Section

  • Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
  • From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
  • Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution
Show more Review Articles

Related Articles

Cited By...

What about you?
Tell us your interests and get all the new contents of Haematologica in advance

 

 

Navigate

  • Home
  • Current issue
  • Ahead of print
  • Archive
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About us
    • About Haematologica
    • Editorial Board
    • Our policies

For Authors

  • Author guidelines
  • Submit Manuscript
  • Track Manuscript

For Reviewers

  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
  • 2014 reviewers

For Advertisers

  • Information For Advertising

Education

  • Review Articles
  • Guideline Articles

More

  • Rights & Permissions
  • Advertising
  • Alerts
  • Feedback
  • Contact
  • App

Copyright © 2019 by the Ferrata Storti Foundation

ISSN 0390-6078 print

ISSN 1592-8721 online